Immunocore (IMCR) Holdings announces that the first patient has been dosed in the Phase 1 trial of IMC-P115C which is a half-life extended ImmTAC candidate. IMC-P115C was developed to improve patient convenience by reducing the frequency of treatment administration. It is Immunocore’s first half-life extended candidate, and sixth ImmTAC candidate to enter the clinic. IMC-P115C is a PRAME x CD3 ImmTAC bispecific protein, with the same CD3 and targeting the same HLA-A*02:01 PRAME, or PReferentially expressed Antigen in MElanoma, peptide as brenetafusp. The Phase 1 dose escalation trial will evaluate the safety, pharmacokinetics and clinical activity of IMC-P115C in HLA-A*02:01-positive patients with a range of advanced cancers expressing PRAME.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Immunocore announces treatment of first patient in Phase 1/2 trial of IMC-R117C
- Immunocore downgraded to Equal Weight from Overweight at Morgan Stanley
- Immunocore, EORTC announce enrollment of first patient in Phase 3 ATOM trial
- Immunocore downgraded to Neutral from Outperform at Mizuho
- Immunocore Holdings Prepares Early Loan Agreement Termination